NasdaqGS - Nasdaq Real Time Price USD

Arvinas, Inc. (ARVN)

6.64

+0.11

+(1.68%)

At close: 4:00:01 PM EDT

6.74

+0.10

+(1.51%)

After hours: 7:19:32 PM EDT

Arvinas, Inc. Just Reported A Surprise Profit And Analysts Updated Their Estimates

There's been a notable change in appetite for Arvinas, Inc. ( NASDAQ:ARVN ) shares in the week since its first-quarter...

Simply Wall St. 16 days ago

ARVN
+1.68%
Here are 1 Main Capital Partners’ Views on Arvinas (ARVN)

1 Main Capital, a boutique investment firm, released its first-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned (3.6)% net in the first quarter compared to (4.3)% and (9.5)% for the S&P 500 (SPX) and Russell 2000 (RTY). Since its inception in February 2018, the fund has returned annualized […]

Insider Monkey 18 days ago

ARVN
+1.68%
Arvinas Inc (ARVN) Q1 2025 Earnings Call Highlights: Record Revenue Surge and Strategic ...

Arvinas Inc (ARVN) reports a significant revenue increase and outlines strategic moves to extend its cash runway and enhance its drug development pipeline.

GuruFocus.com 18 days ago

ARVN
+1.68%

PFE
Arvinas, Inc. (ARVN) Q1 Earnings and Revenues Beat Estimates

Arvinas (ARVN) delivered earnings and revenue surprises of 232.56% and 332.53%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 19 days ago

ARVN
+1.68%
Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update

– Reported positive topline results from the Phase 3 VERITAC-2 trial that support global regulatory filings – – Presented first-in-human data for the Company’s first neuroscience program with ARV-102 showing blood-brain barrier penetration and central and peripheral LRRK2 degradation – – Announced the re-prioritization of its vepdegestrant development plan and research portfolio and initiated cost reductions, including a workforce reduction of approximately one-third, to extend the Company’s cas

GlobeNewswire 19 days ago

ARVN
+1.68%
Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Apellis Pharmaceuticals (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 21 days ago

APLS

ARVN
+1.68%
Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

NEW HAVEN, Conn., April 28, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that management will review first quarter 2025 financial results and provide a corporate update during a live webcast on Thursday, May 1, 2025, at 8:00 a.m. ET. The webcast can be accessed under “Events and Presentations” on the investor page of the Arvinas website. A replay of the

GlobeNewswire 22 days ago

ARVN
+1.68%
Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting

– ARV-393 demonstrated strong synergistic antitumor activity, including complete regressions, in combination with standard-of-care chemotherapy, biologics, and select investigational oral small molecule inhibitors – – Findings support continued evaluation of ARV-393 combinations in non-Hodgkin lymphoma – NEW HAVEN, Conn., April 28, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degrad

GlobeNewswire 22 days ago

ARVN
+1.68%
Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

– Oral presentation will serve as first presentation of detailed results from the Phase 3 VERITAC-2 clinical trial – NEW HAVEN, Conn., April 23, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that data from the global Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant versus fulvestrant in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer will be presented as a l

GlobeNewswire 27 days ago

ARVN
+1.68%
Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Meeting

Company to highlight preclinical study of ARV-393, an investigational PROTAC BCL6 degrader, in combination with standard of care therapiesNEW HAVEN, Conn., April 21, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that new preclinical combination data for ARV-393 will be presented at the American Association for Cancer Research® (AACR) Annual meeting, April

GlobeNewswire 29 days ago

ARVN
+1.68%
Arvinas, Inc. (ARVN): Among Stocks Under $10 that Will Triple

We recently published a list of 10 Stocks Under $10 that Will Triple. In this article, we are going to take a look at where Arvinas, Inc. (NASDAQ:ARVN) stands against other stocks under $10 that will triple. As we delve into the discussion on stocks that will triple, we must shed light on the U.S. […]

Insider Monkey last month

ARVN
+1.68%
After Plunging -25.42% in 4 Weeks, Here's Why the Trend Might Reverse for Arvinas (ARVN)

The heavy selling pressure might have exhausted for Arvinas (ARVN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks last month

ARVN
+1.68%
Arvinas Potential Parkinson's Treatment Shows Positive Data In Human Study

Arvinas, Inc. (NASDAQ:ARVN) unveiled first-in-human data on Friday for its experimental Parkinson’s disease treatment, ARV-102. Results from the randomized, double-blind, placebo-controlled single ascending dose (SAD) cohort of the Phase 1 healthy volunteer trial and initial results from the multiple ascending dose (MAD) cohort were shared in a presentation at the 2025 International Conference on Alzheimer’s and Parkinson’s Diseases. The Phase 1 trial included SAD cohorts from 10 mg to 200 mg an

Benzinga last month

ARVN
+1.68%
Arvinas’ PROTAC halves protein suspected to play role in Parkinson’s

In the Phase I trial, the therapy was relatively well tolerated, with some adverse events (AEs) reported.

Clinical Trials Arena last month

ARVN
+1.68%
Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation

– Data demonstrate that ARV-102 was well tolerated, orally bioavailable, and brain-penetrant; ARV-102 achieved central and peripheral LRRK2 reduction indicating substantial LRRK2 protein degradation in healthy volunteers – – Findings support continued evaluation of ARV-102 in neurodegenerative diseases associated with LRRK2 dysfunction; a Phase 1 trial in patients with Parkinson's disease has been initiated and is currently enrolling – NEW HAVEN, Conn., April 04, 2025 (GLOBE NEWSWIRE) -- Arvinas

GlobeNewswire last month

ARVN
+1.68%
We Think Arvinas (NASDAQ:ARVN) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. last month

ARVN
+1.68%
Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases

– Company to highlight first-in-human data from healthy volunteers in both the single-ascending and multiple-ascending dose portions of a Phase 1 study of ARV-102, an investigational PROTAC LRRK2 degrader –NEW HAVEN, Conn., March 27, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that data from the first-in-human study evaluating single-ascending and multi

GlobeNewswire last month

ARVN
+1.68%
Down -54.85% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround

Arvinas (ARVN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks 2 months ago

ARVN
+1.68%
Is Arvinas, Inc. (ARVN) a Pump and Dump Stock Favored by Hedge Funds?

We recently compiled a list of the 10 Pump and Dump Stocks Favored by Hedge Funds. In this article, we are going to take a look at where Arvinas, Inc. (NASDAQ:ARVN) stands against the pump and dump stocks. Pump and dump stocks are typically characterized by high 52-week volatility, often experiencing rapid price surges followed […]

Insider Monkey 2 months ago

ARVN
+1.68%
Strength Seen in BioHarvest Sciences Inc. (BHST): Can Its 12.7% Jump Turn into More Strength?

BioHarvest Sciences Inc. (BHST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks 2 months ago

ARVN
+1.68%

Performance Overview

Return	ARVN	S&P 500 (^GSPC)
YTD	-65.36%	+1.00%
1-Year	-80.04%	+11.91%
3-Year	-85.13%	+52.27%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Arvinas, Inc. (ARVN)

Arvinas, Inc. Just Reported A Surprise Profit And Analysts Updated Their Estimates

Here are 1 Main Capital Partners’ Views on Arvinas (ARVN)

Arvinas Inc (ARVN) Q1 2025 Earnings Call Highlights: Record Revenue Surge and Strategic ...

Arvinas, Inc. (ARVN) Q1 Earnings and Revenues Beat Estimates

Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting

Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Meeting

Arvinas, Inc. (ARVN): Among Stocks Under $10 that Will Triple

After Plunging -25.42% in 4 Weeks, Here's Why the Trend Might Reverse for Arvinas (ARVN)

Arvinas Potential Parkinson's Treatment Shows Positive Data In Human Study

Arvinas’ PROTAC halves protein suspected to play role in Parkinson’s

Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation

We Think Arvinas (NASDAQ:ARVN) Can Afford To Drive Business Growth

Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases

Down -54.85% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround

Is Arvinas, Inc. (ARVN) a Pump and Dump Stock Favored by Hedge Funds?

Strength Seen in BioHarvest Sciences Inc. (BHST): Can Its 12.7% Jump Turn into More Strength?

Performance Overview